Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 134

Similar articles for PubMed (Select 23508758)

1.

Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients.

Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L, Vanderloo SE, McAlister FA.

Circ Heart Fail. 2013 May;6(3):395-402. doi: 10.1161/CIRCHEARTFAILURE.112.000162. Epub 2013 Mar 18. Review.

2.

Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

Salpeter S, Greyber E, Pasternak G, Salpeter E.

Cochrane Database Syst Rev. 2003;(2):CD002967. Review. Update in: Cochrane Database Syst Rev. 2006;(1):CD002967.

PMID:
12804446
3.

Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

Salpeter S, Greyber E, Pasternak G, Salpeter E.

Cochrane Database Syst Rev. 2002;(2):CD002967. Review. Update in: Cochrane Database Syst Rev. 2003;(2):CD002967.

PMID:
12076461
4.

Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review.

Eurich DT, McAlister FA, Blackburn DF, Majumdar SR, Tsuyuki RT, Varney J, Johnson JA.

BMJ. 2007 Sep 8;335(7618):497. Epub 2007 Aug 30. Review.

5.

Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

Salpeter S, Greyber E, Pasternak G, Salpeter E.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD002967. Review. Update in: Cochrane Database Syst Rev. 2010;(1):CD002967.

PMID:
16437448
6.

Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

Salpeter SR, Greyber E, Pasternak GA, Salpeter EE.

Cochrane Database Syst Rev. 2010 Apr 14;(4):CD002967. doi: 10.1002/14651858.CD002967.pub4. Review.

PMID:
20393934
7.

Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

Salpeter SR, Greyber E, Pasternak GA, Salpeter Posthumous EE.

Cochrane Database Syst Rev. 2010 Jan 20;(1):CD002967. doi: 10.1002/14651858.CD002967.pub3. Review. Update in: Cochrane Database Syst Rev. 2010;(4):CD002967.

PMID:
20091535
8.

Improved clinical outcomes associated with metformin in patients with diabetes and heart failure.

Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA.

Diabetes Care. 2005 Oct;28(10):2345-51.

PMID:
16186261
9.

The safety of metformin in heart failure.

Roberts F, Ryan GJ.

Ann Pharmacother. 2007 Apr;41(4):642-6. Epub 2007 Mar 20. Review.

PMID:
17374622
10.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
11.

[Efficacy and safety of the use of metformin in patients with chronic heart failure and type 2 diabetes mellitus. results of the study "rational effective mulicomponent therapy in the battle against diabetes mellitus in patients with chronic heart failure"].

Lapina IuV, Narusov OIu, Mareev VIu, Bolotina MG, Shestakova MV, Masenko VP, Litonova GN, Arzamastseva NE, Baklanova NA, Belenkov IuN.

Kardiologiia. 2008;48(3):58-68. Russian.

PMID:
18429758
12.

Metformin in patients with type 2 diabetes and kidney disease: a systematic review.

Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK.

JAMA. 2014 Dec 24-31;312(24):2668-75. doi: 10.1001/jama.2014.15298. Review.

13.
14.

[Metformin and insulin in chronic heart failure: contraindications not contraindicated and indications not indicated].

Cosmi F, Cosmi D.

G Ital Cardiol (Rome). 2011 Dec;12(12):796-803. doi: 10.1714/996.10824. Review. Italian.

PMID:
22158450
15.

Metformin use and mortality in ambulatory patients with diabetes and heart failure.

Aguilar D, Chan W, Bozkurt B, Ramasubbu K, Deswal A.

Circ Heart Fail. 2011 Jan;4(1):53-8. doi: 10.1161/CIRCHEARTFAILURE.110.952556. Epub 2010 Oct 15.

16.

How should subgroup analyses affect clinical practice? Insights from the Metoprolol Succinate Controlled-Release/Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF).

Wikstrand J, Wedel H, Ghali J, Deedwania P, Fagerberg B, Goldstein S, Gottlieb S, Hjalmarson A, Kjekshus J, Waagstein F.

Card Electrophysiol Rev. 2003 Sep;7(3):264-75.

PMID:
14739726
17.

Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study.

Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM.

Circulation. 2005 Feb 8;111(5):583-90.

18.

Evaluating the potential benefits of metformin in patients with cardiovascular disease and heart failure.

Norwood DK, Chilipko AA, Amin SM, Macharia D, Still KL.

Consult Pharm. 2013 Sep;28(9):579-83. doi: 10.4140/TCP.n.2013.579.

PMID:
24007890
19.

Metformin use in decompensated heart failure.

Boyd A, Nawarskas J.

Cardiol Rev. 2008 Sep-Oct;16(5):269-72. doi: 10.1097/CRD.0b013e3181846c53.

PMID:
18708828
20.

Metformin: effective and safe in renal disease?

Herrington WG, Levy JB.

Int Urol Nephrol. 2008;40(2):411-7. doi: 10.1007/s11255-008-9371-6. Review.

PMID:
18368503
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk